Prevalence of benzodiazepines and benzodiazepine-related drugs exposure before, during and after pregnancy: A systematic review and meta-analysis
- PMID: 32217339
- DOI: 10.1016/j.jad.2020.03.014
Prevalence of benzodiazepines and benzodiazepine-related drugs exposure before, during and after pregnancy: A systematic review and meta-analysis
Abstract
Background: Maternal use of benzodiazepines during pregnancy is common and has increased over the last decades. In this systematic review and meta-analysis, we studied the literature to estimate the worldwide use of benzodiazepines before, during and after pregnancy, which could help to estimate benzodiazepine exposure and to prioritize and guide future investigations.
Methods: We systematically searched Embase, Medline Ovid, Web of Science and Cochrane Central up until July 2019 for studies reporting on benzodiazepine use before (12 months), during and after pregnancy (12 months). Random effects meta-analysis was conducted to calculate pooled prevalence estimates, as well as stratified according to substantive variables.
Results: We identified 32 studies reporting on 28 countries, together reporting on 7,343,571 pregnancies. The worldwide prevalence of benzodiazepine use/prescriptions during pregnancy was 1.9% (95%CI 1.6%-2.2%; I2 97.48%). Highest prevalence was found in the third trimester (3.1%; 95%CI 1.8%-4.5%; I2 99.83%). Lorazepam was the most frequently used/prescribed benzodiazepine (1.5%; 95%CI 0.5%-2.5%; I2 99.87%). Highest prevalence was found in Eastern Europe (14.0%; 95%CI 12.1%-15.9%; I2 0.00%).
Limitations: All analyses revealed considerable heterogeneity.
Conclusions: Our meta-analysis confirmed that benzodiazepine use before, during and after pregnancy is prevalent. The relatively common use of benzodiazepines with possible risks for both mother and (unborn) child is worrying and calls for prescription guidelines for women, starting in the preconception period. Given the substantial proportion of children exposed to benzodiazepines in utero, future research should continue to study the short- and long-term safety of maternal benzodiazepine use during pregnancy and to explore non-pharmacological alternative treatments.
Keywords: Benzodiazepines; Meta-analysis; Postpartum period; Pregnancy; Prescription drugs.
Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest None.
Similar articles
-
Association of Maternal Use of Benzodiazepines and Z-Hypnotics During Pregnancy With Motor and Communication Skills and Attention-Deficit/Hyperactivity Disorder Symptoms in Preschoolers.JAMA Netw Open. 2019 Apr 5;2(4):e191435. doi: 10.1001/jamanetworkopen.2019.1435. JAMA Netw Open. 2019. PMID: 30951155 Free PMC article.
-
Association Between Incident Exposure to Benzodiazepines in Early Pregnancy and Risk of Spontaneous Abortion.JAMA Psychiatry. 2019 Sep 1;76(9):948-957. doi: 10.1001/jamapsychiatry.2019.0963. JAMA Psychiatry. 2019. PMID: 31090881 Free PMC article.
-
First trimester exposure to anxiolytic and hypnotic drugs and the risks of major congenital anomalies: a United Kingdom population-based cohort study.PLoS One. 2014 Jun 25;9(6):e100996. doi: 10.1371/journal.pone.0100996. eCollection 2014. PLoS One. 2014. PMID: 24963627 Free PMC article.
-
[In utero exposure to benzodiazepine. Is there a risk for anal atresia with lorazepam?].Encephale. 2003 Nov-Dec;29(6):553-9. Encephale. 2003. PMID: 15029090 Review. French.
-
The international prevalence of antidepressant use before, during, and after pregnancy: A systematic review and meta-analysis of timing, type of prescriptions and geographical variability.J Affect Disord. 2020 Mar 1;264:82-89. doi: 10.1016/j.jad.2019.12.014. Epub 2019 Dec 9. J Affect Disord. 2020. PMID: 31846905 Review.
Cited by
-
Navigating the Complexity of a Bipolar Pregnant Patient With Multiple Comorbidities.Cureus. 2024 Jan 2;16(1):e51510. doi: 10.7759/cureus.51510. eCollection 2024 Jan. Cureus. 2024. PMID: 38304661 Free PMC article.
-
Benzodiazepine Use During Pregnancy and Risk of Miscarriage.JAMA Psychiatry. 2023 Dec 27:e234912. doi: 10.1001/jamapsychiatry.2023.4912. Online ahead of print. JAMA Psychiatry. 2023. PMID: 38150230
-
Academy of Breastfeeding Medicine Clinical Protocol #21: Breastfeeding in the Setting of Substance Use and Substance Use Disorder (Revised 2023).Breastfeed Med. 2023 Oct;18(10):715-733. doi: 10.1089/bfm.2023.29256.abm. Breastfeed Med. 2023. PMID: 37856658
-
Principles of care for pregnant and parenting people with substance use disorder: the obstetrician gynecologist perspective.Front Pediatr. 2023 May 24;11:1045745. doi: 10.3389/fped.2023.1045745. eCollection 2023. Front Pediatr. 2023. PMID: 37292372 Free PMC article. Review.
-
Association of maternal personality traits with medication use during pregnancy to appraise unmeasured confounding in long-term pharmacoepidemiological safety studies.Front Pharmacol. 2023 May 15;14:1160168. doi: 10.3389/fphar.2023.1160168. eCollection 2023. Front Pharmacol. 2023. PMID: 37256227 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
